Cencora
COR
Market cap $56.7B

288.30 USD

-4.30

1.47%

At close Aug 25, 4:00 PM EDT

After hours

288.30

+0.00

0.00%

1 day

-1.47%

5 days

-0.58%

1 month

-0.71%

3 months

-1.73%

6 months

15.08%

Year to date

28.28%

1 year

22.97%

5 years

193.35%

10 years

195.97%

About: Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Employees: 46,000

Healthcare Medical Distribution

0

Funds holding %

of 7,429 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

84% more first-time investments, than exits

New positions opened: 166 | Existing positions closed: 90

47% more call options, than puts

Call options by funds: $1.2B | Put options by funds: $820M

7% more capital invested

Capital invested by funds: $51.5B [Q1] → $54.9B (+$3.45B) [Q2]

3% more funds holding

Funds holding: 1,273 [Q1] → 1,317 (+44) [Q2]

5% more repeat investments, than reductions

Existing positions increased: 489 | Existing positions reduced: 466

0.83% less ownership

Funds ownership: 95.44% [Q1] → 94.6% (-0.83%) [Q2]

22% less funds holding in top 10

Funds holding in top 10: 27 [Q1] → 21 (-6) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$300

4%

upside

Avg. target

$328

14%

upside

High target

$354

23%

upside

3 analyst ratings

1 positive

33%

2 neutral

67%

0 negative

0%

Wells Fargo Stephen Baxter	23%upside $354	Overweight Maintained	13 Aug 2025
Morgan Stanley Erin Wright	14%upside $330	Equal-Weight Maintained	16 Jul 2025
Jefferies Jonathan Petersen	4%upside $300	Hold Maintained	30 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 13 articles about COR published over the past 30 days

Zacks Investment Research

Why Cencora (COR) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Cencora (COR) is a Top Value Stock for the Long-Term

Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap

Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results should fade in the coming quarters. The valuation remains elevated at 17.9x forward P/E, well above the 5-year average, making the risk/reward unattractive at current levels. Key risks include heavy revenue exposure to Walgreens Boots Alliance, which faces solvency issues and plans to sell its COR stake.

Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap

Zacks Investment Research

3 Reasons Growth Investors Will Love Cencora (COR)

Cencora (COR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Growth Investors Will Love Cencora (COR)

Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy

I initiate Cencora, Inc. with a Buy rating and a fair value of $337, due to its stable business model and strategic specialty drug expansion. Cencora's acquisition of Retina Consultants of America and focus on GLP-1 drugs strengthen its specialty solutions, supporting long-term growth and margin improvement. Management's commitment to digital infrastructure and specialty expertise positions Cencora to benefit from robust U.S. pharmaceutical sales growth and healthcare trends.

Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy

Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript

Cencora, Inc. (NYSE:COR ) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F.

Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript

Zacks Investment Research

COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised

Cencora posts strong Q3 results with earnings and revenues surpassing estimates; raises FY25 EPS guidance on robust U.S. segment growth.

COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised

Zacks Investment Research

Cencora (COR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cencora (COR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

Cencora (COR) Q3 Earnings and Revenues Surpass Estimates

Cencora (COR) came out with quarterly earnings of $4 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $3.34 per share a year ago.

Cencora (COR) Q3 Earnings and Revenues Surpass Estimates

Cencora raises annual profit forecast on strong demand for specialty drugs

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped Wall Street estimates, buoyed by surging demand for specialty therapies and blockbuster weight-loss drugs.

Cencora raises annual profit forecast on strong demand for specialty drugs

Cencora Reports Fiscal 2025 Third Quarter Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.52 for the third quarter of fiscal 2025 compared to $2.42 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, inc.

Cencora Reports Fiscal 2025 Third Quarter Results

See News Rankings

Charts implemented using Lightweight Charts™